Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture

Table 4 summary of data from recent reports including salvage therapy with three angiogenesis inhibitors plus chemotherapy

Treatment	Line	No. of patients	mTTP mo	MST mo	AE (grade ≥ 3)
FOLFIRI + Rmab[19]	3rd or later	13	4	6.1	NA
FOLFIRI + Rmab[20]	2nd	22	5.4	17.4	Neutropenia (54%)
					Hypertension (4%)
					Proteinuria (8%)
FOLFIRI + Rmab[20]	3rd or later	17	2.8	13	Neutropenia (35%)
					Hypertension (6%)
					Proteinuria (24%)
Cx + Bmab[21]	3rd or later	42	5.3	9.5	Neutropenia (43%)
					Hypertension (5%)
Cx + Bmab[22]	3rd or later	46	8.9	13.8	NA
Cx + Bmab[23]	2nd	154	8.5	19.1	Neutropenia (4%)
					Hypertension (1%)
Cx + Bmab[23]	3rd or later	62	6.3	14.9	Neutropenia (2%)
					Hypertension (2%)
					Proteinuria (2%)
FOLFIRI + AFL[18]	2nd	54	4.4	11.9	Neutropenia (9%)
					Hypertension (6%)
					Proteinuria (2%)
FOLFIRI + AFL[18]	3rd	69	4.3	11.1	Included in the above
FOLFIRI + AFL[18]	4th	47	3.4	8.1	Included in the above
FOLFIRI + AFL1	2nd	22	4.1	22.4	Neutropenia (14%)
					Hypertension (9%)
					Proteinuria (5%)
FOLFIRI + AFL1	3rd or later	19	2.4	13.2	Neutropenia (11%)
					Hypertension (5%)
					Proteinuria (11%)

¹They are our results.

mTTP: Median time to progression; MST: Median survival time; AE: Adverse event; Rmab: Ramucirumab; Cx: Chemotherapy (FOLFIRI or FOLFOX); Bmab: Bevacizumab; AFL: Aflibercept; FOLFIRI: Folinic acid-fluorouracil-irinotecan.